
|Articles|July 1, 2003
VISX gets OK from FDA; investors block takeover
Santa Clara, CA-VISX Inc. is celebrating the FDA approval of its CustomVue laser-vision correction procedure, as its board survived an attempt to dethrone one member in a takeover plan by financier Carl C. Icahn.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
2
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
3
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
4
Study shows significant ocular changes following hemodialysis
5














































